Workflow
Fudan-Zhangjiang(01349)
icon
Search documents
智通AH统计|8月28日
智通财经网· 2025-08-28 08:21
Group 1 - The article highlights the top three companies with the highest AH premium rates as Northeast Electric (00042) at 785.25%, Hongye Futures (03678) at 250.59%, and Andeli Juice (02218) at 244.32% [1] - The bottom three companies with the lowest AH premium rates include Ningde Times (03750) at -18.40%, Hengrui Medicine (01276) at 3.92%, and China Merchants Bank (03968) at 7.34% [1] - The article provides a detailed ranking of the top ten and bottom ten AH stocks based on their premium rates and deviation values, indicating significant disparities in market valuations between H-shares and A-shares [1][2] Group 2 - The top three companies with the highest deviation values are Jinli Permanent Magnet (06680) at 37.37%, Andeli Juice (02218) at 33.98%, and Fudan Zhangjiang (01349) at 22.87% [1] - Conversely, the bottom three companies with the lowest deviation values are BYD Company (01211) at -75.67%, Longpan Technology (02465) at -57.24%, and Changfei Optical Fiber Cable (06869) at -31.37% [1][2] - The article emphasizes the importance of monitoring these premium rates and deviation values as indicators of potential investment opportunities and market inefficiencies [1][2]
复旦张江(688505.SH):王海波拟减持不超过10万股公司股份
Ge Long Hui A P P· 2025-08-27 11:29
Core Viewpoint - Fudan Zhangjiang (688505.SH) announced that Mr. Wang Haibo plans to reduce his shareholding in the company due to personal funding needs, intending to sell up to 100,000 shares within three months after the announcement, which represents a maximum of 0.01% of the company's total share capital [1] Summary by Relevant Categories Shareholding Reduction - Mr. Wang Haibo intends to reduce his holdings through centralized bidding, with a maximum reduction of 100,000 shares [1] - The planned reduction accounts for no more than 0.01% of the total share capital of Fudan Zhangjiang [1]
复旦张江(688505) - 复旦张江关于持股5%以上股东减持股份计划公告
2025-08-27 11:16
证券代码:688505 证券简称:复旦张江 公告编号:临 2025-028 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示: 大股东持股的基本情况 截至本公告披露日,上海复旦张江生物医药股份有限公司(以下简称"公司" 或"复旦张江")股东王海波先生持有公司股份 51,828,605 股,占公司总股本的 5.00%。王海波先生所持有的公司股份来源为公司首次公开发行前取得的股份, 该部分股份已于 2023 年 6 月 19 日起全部解除限售并上市流通。 减持计划的主要内容 公司于近日收到王海波先生发来的《关于减持复旦张江股份计划的告知函》, 因自身资金需求,王海波先生计划自本公告披露之日起 15 个交易日后的 3 个月 内通过集中竞价的方式减持公司股份不超过 100,000 股,拟减持比例不超过公司 总股本的 0.01%。 根据王海波先生于《复旦张江首次公开发行股票并在科创板上市招股说明书》 作出的承诺:"本人减持所持有公司股份 ...
复旦张江股东王海波拟减持不超过10万股A股
Zhi Tong Cai Jing· 2025-08-27 11:00
Core Viewpoint - Fudan Zhangjiang Biopharmaceutical Co., Ltd. announced that shareholder Wang Haibo holds 51.8286 million shares, representing 5.00% of the total share capital, and plans to reduce his holdings due to personal funding needs [1] Group 1 - Wang Haibo's shares were acquired before the company's initial public offering and have been fully released from restrictions since June 19, 2023 [1] - Wang Haibo intends to reduce his holdings by no more than 100,000 shares within three months, which would account for up to 0.01% of the company's total share capital [1]
复旦张江(01349) - 海外监管公告-上海復旦张江生物医药股份有限公司关於持股 5%以上股东减持...
2025-08-27 10:52
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃上海復旦張江生物醫藥股份有限公司(「本公司」)根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司關 於持股 5%以上股東減持股份計劃公告》,僅供參閱。該文件及其披露內容乃根據中國 法律法規及境內相關監管要求而編制及刊發。 承董事會命 趙大君 主 席 於本公告刊發日期,董事會包括以下人士: 趙大君先生(執行董事) 中國·上海 二零二五年八月二十七日 *僅供識別 证券代码:688505 证券简称:复旦张江 公告编号:临 2025-028 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示: 大股东持股的基本情况 截至本 ...
智通AH统计|8月27日
Zhi Tong Cai Jing· 2025-08-27 08:26
Core Insights - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 770.97%, Hongye Futures (03678) at 252.57%, and Andeli Juice (02218) at 238.08% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -18.73%, Midea Group (00300) at 6.86%, and Heng Rui Medicine (01276) at 7.43% [1][2] - The companies with the highest deviation values are Beijing Machinery (00187) at 32.43%, Andeli Juice (02218) at 29.55%, and Fudan Zhangjiang (01349) at 29.44% [1][3] - The companies with the lowest deviation values are BYD (01211) at -84.97%, Longpan Technology (02465) at -62.46%, and GAC Group (02238) at -26.17% [1][3] AH Premium Rate Rankings - The top AH stocks by premium rate include: - Northeast Electric (00042): H-share at 0.310 HKD, A-share at 2.25 CNY, premium rate 770.97%, deviation -23.02% [2] - Hongye Futures (03678): H-share at 4.280 HKD, A-share at 12.6 CNY, premium rate 252.57%, deviation 25.11% [2] - Andeli Juice (02218): H-share at 17.780 HKD, A-share at 50.18 CNY, premium rate 238.08%, deviation 29.55% [2] - The bottom AH stocks by premium rate include: - CATL (03750): H-share at 410.200 HKD, A-share at 278.3 CNY, premium rate -18.73%, deviation 1.21% [2] - Midea Group (00300): H-share at 81.500 HKD, A-share at 72.71 CNY, premium rate 6.86%, deviation -1.78% [2] - Heng Rui Medicine (01276): H-share at 72.500 HKD, A-share at 65.03 CNY, premium rate 7.43%, deviation 11.64% [2] Deviation Value Rankings - The top AH stocks by deviation value include: - Beijing Machinery (00187): H-share at 4.950 HKD, A-share at 13.24 CNY, premium rate 220.40%, deviation 32.43% [3] - Andeli Juice (02218): H-share at 17.780 HKD, A-share at 50.18 CNY, premium rate 238.08%, deviation 29.55% [3] - Fudan Zhangjiang (01349): H-share at 3.590 HKD, A-share at 10.06 CNY, premium rate 235.65%, deviation 29.44% [3] - The bottom AH stocks by deviation value include: - BYD (01211): H-share at 115.100 HKD, A-share at 110.68 CNY, premium rate 15.18%, deviation -84.97% [3] - Longpan Technology (02465): H-share at 10.320 HKD, A-share at 14.37 CNY, premium rate 66.76%, deviation -62.46% [3] - GAC Group (02238): H-share at 3.690 HKD, A-share at 7.88 CNY, premium rate 155.83%, deviation -26.17% [3]
智通AH统计|8月25日
智通财经网· 2025-08-25 08:21
Group 1 - The article highlights the top three companies with the highest AH premium rates as Northeast Electric (00042) at 743.75%, Hongye Futures (03678) at 241.98%, and Andeli Juice (02218) at 236.37% [1] - The bottom three companies with the lowest AH premium rates include Ningde Times (03750) at -16.43%, Heng Rui Medicine (01276) at 1.82%, and Midea Group (00300) at 4.90% [1] - The article provides a detailed table of the top ten and bottom ten AH stocks based on premium rates and deviation values, indicating significant disparities in market valuations between H-shares and A-shares [1][2] Group 2 - The deviation values for the top three companies are Andeli Juice (02218) at 32.29%, Jinli Permanent Magnet (06680) at 22.19%, and Beijing Machinery (00187) at 20.80% [1] - The companies with the lowest deviation values include BYD Company (01211) at -98.36%, Northeast Electric (00042) at -64.84%, and Longpan Technology (02465) at -51.92% [1][2] - The article emphasizes that the deviation value represents the difference between the current premium rate and the average premium rate over the past 30 days, providing insights into market trends [2]
智通AH统计|8月21日
Zhi Tong Cai Jing· 2025-08-21 08:41
Core Insights - The article highlights the top and bottom AH share premium rates as of August 21, with Northeast Electric (00042), Andeli Juice (02218), and Hongye Futures (03678) leading in premium rates, while CATL (03750), Heng Rui Medicine (01276), and Midea Group (00300) lag behind [1][2] Premium Rate Summary - The top three AH share premium rates are as follows: - Northeast Electric (00042): 757.14% - Andeli Juice (02218): 237.73% - Hongye Futures (03678): 236.54% [2] - The bottom three AH share premium rates are: - CATL (03750): -17.69% - Heng Rui Medicine (01276): -2.65% - Midea Group (00300): 5.19% [2] Deviation Value Summary - The top three stocks with the highest deviation values are: - Andeli Juice (02218): 38.61% - Beijing Machinery (00187): 30.46% - Junda Co. (02865): 17.54% [1][3] - The bottom three stocks with the lowest deviation values are: - BYD (01211): -111.35% - Northeast Electric (00042): -64.92% - Longpan Technology (02465): -46.48% [1][3]
8月19日复旦张江AH溢价达183.21%,位居AH股溢价率第三位
Jin Rong Jie· 2025-08-19 09:04
Group 1 - The Shanghai Composite Index fell by 0.02% to close at 3727.29 points, while the Hang Seng Index decreased by 0.21% to 25122.9 points [1] - Fudan Zhangjiang's A/H premium reached 183.21%, ranking third among A/H shares [1] - At market close, Fudan Zhangjiang's A-shares were priced at 10.48 yuan, down 1.87%, and H-shares were at 4.02 HKD, down 1.95% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage forms, with new drugs expected to be launched in the market [1] - The company has undertaken several national key science and technology projects, including the "National Key Technology R&D Program," "National High Technology Research and Development Program (863 Program)," and "Major New Drug Creation" projects [1]
8月18日复旦张江AH溢价达183.79%,位居AH股溢价率第三位
Jin Rong Jie· 2025-08-18 08:45
Group 1 - The Shanghai Composite Index rose by 0.85% to close at 3728.03 points, while the Hang Seng Index fell by 0.37% to close at 25176.85 points [1] - Fudan Zhangjiang's A/H premium reached 183.79%, ranking third among A/H shares [1] - Fudan Zhangjiang's A-shares closed at 10.68 yuan, with a gain of 2.01%, and H-shares closed at 4.1 Hong Kong dollars, up by 2.24% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a knowledge-based innovative enterprise [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage technology, with new drugs expected to be launched in the market [1]